CalciMedica Inc. (NASDAQ:CALC) Receives Average Recommendation of “Hold” from Brokerages

Shares of CalciMedica Inc. (NASDAQ:CALC) have been assigned a consensus rating of “Hold” from the five analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $10.00.

A number of equities analysts have commented on CALC shares. HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. Weiss Ratings downgraded CalciMedica from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Guggenheim started coverage on shares of CalciMedica in a report on Thursday. They set a “buy” rating for the company. Finally, UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th.

Insider Buying and Selling at CalciMedica

In other news, Director Fred A. Middleton purchased 248,972 shares of CalciMedica stock in a transaction that occurred on Thursday, June 25th. The shares were bought at an average cost of $0.80 per share, with a total value of $199,177.60. Following the completion of the purchase, the director directly owned 1,063,272 shares in the company, valued at approximately $850,617.60. This trade represents a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 28.25% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CalciMedica

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in shares of CalciMedica in the fourth quarter worth $127,000. Cetera Investment Advisers increased its holdings in CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after buying an additional 9,045 shares in the last quarter. PVG Asset Management Corp bought a new stake in shares of CalciMedica in the fourth quarter worth approximately $302,000. Boothbay Fund Management LLC purchased a new stake in CalciMedica during the 4th quarter valued at $506,000. Finally, Renaissance Technologies LLC increased its position in CalciMedica by 26.1% during the fourth quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after acquiring an additional 18,300 shares during the last quarter.

CalciMedica Stock Down 3.9%

CALC stock opened at $0.61 on Thursday. The stock has a 50-day simple moving average of $0.79 and a two-hundred day simple moving average of $0.71. The firm has a market capitalization of $9.69 million, a PE ratio of -0.45 and a beta of 0.91. CalciMedica has a twelve month low of $0.46 and a twelve month high of $7.20. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 1.67.

CalciMedica (NASDAQ:CALC) last posted its earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.17). On average, equities analysts predict that CalciMedica will post -1.05 EPS for the current fiscal year.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.